An explanation of the new directive on clinical trials by the Drugs Controller General of India (DCGI) in IndiaMarsh explains a change in the regulations that apply to clinical trials in India and the responsibilities placed upon Contract Research Organisations (CROs). An interesting development is that we are aware that ethics committees have, in some cases, widened the scope of the Drugs Controller General of India (DCGI) trial approval letters which can create an additional exposure.